View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsKolinpharma 배당 및 자사주 매입배당 기준 점검 0/6Kolinpharma 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률1.4%자사주 매입 수익률총 주주 수익률1.4%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jun 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €9.45, the stock trades at a trailing P/E ratio of 44.4x. Average forward P/E is 23x in the Personal Products industry in Italy. Total returns to shareholders of 6.4% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.99 per share.분석 기사 • Jun 17Kolinpharma (BIT:KIP) Is Looking To Continue Growing Its Returns On CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Reported Earnings • Mar 24Full year 2022 earnings releasedFull year 2022 results: Revenue: €15.6m (up 23% from FY 2021). Net income: €342.3k (down 46% from FY 2021). Profit margin: 2.2% (down from 5.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.8% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Personal Products industry in Italy.Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improved over the past weekAfter last week's 19% share price gain to €8.40, the stock trades at a trailing P/E ratio of 58x. Average forward P/E is 21x in the Personal Products industry in Italy. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.25 per share.분석 기사 • Dec 01What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?Kolinpharma S.p.A. ( BIT:KIP ), is not the largest company out there, but it saw significant share price movement...Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Chairman of the Board of Statutory Auditors Pierluigi Pipolo was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0.23 in 1H 2021)First half 2022 results: EPS: €0 (down from €0.23 in 1H 2021). Revenue: €6.90m (up 13% from 1H 2021). Net loss: €26.9k (down 107% from profit in 1H 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Personal Products industry in Italy.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Chairman of the Board of Statutory Auditors Pierluigi Pipolo was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Price Target Changed • Apr 14Price target increased to €13.45Up from €12.38, the current price target is an average from 2 analysts. New target price is 60% above last closing price of €8.42. Stock is up 2.7% over the past year.Buying Opportunity • Apr 06Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 7.7%. The fair value is estimated to be €11.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company has become profitable.Buying Opportunity • Feb 04Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 6.1%. The fair value is estimated to be €11.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% per annum over the last 3 years. The company has become profitable over the last 3 years.Reported Earnings • Oct 01First half 2021 earnings releasedThe company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €6.53m (up 110% from 1H 2020). Net income: €374.9k (up €502.6k from 1H 2020). Profit margin: 5.7% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 26% share price gain to €10.30, the stock trades at a trailing P/E ratio of 26.3x. Average forward P/E is 32x in the Personal Products industry in Europe. Total returns to shareholders of 48% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €17.98 per share.분석 기사 • Aug 25An Intrinsic Calculation For Kolinpharma S.p.A. (BIT:KIP) Suggests It's 46% UndervaluedDoes the August share price for Kolinpharma S.p.A. ( BIT:KIP ) reflect what it's really worth? Today, we will estimate...분석 기사 • Jun 08We Think Kolinpharma (BIT:KIP) Can Stay On Top Of Its DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • May 21Do Kolinpharma's (BIT:KIP) Earnings Warrant Your Attention?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...분석 기사 • May 03Is There An Opportunity With Kolinpharma S.p.A.'s (BIT:KIP) 35% Undervaluation?Today we will run through one way of estimating the intrinsic value of Kolinpharma S.p.A. ( BIT:KIP ) by taking the...분석 기사 • Apr 13Some Shareholders Feeling Restless Over Kolinpharma S.p.A.'s (BIT:KIP) P/E RatioWith a price-to-earnings (or "P/E") ratio of 22.3x Kolinpharma S.p.A. ( BIT:KIP ) may be sending bearish signals at the...Reported Earnings • Apr 01Full year 2020 earnings releasedThe company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: €9.52m (down 4.8% from FY 2019). Net income: €642.4k (up 8.6% from FY 2019). Profit margin: 6.7% (up from 5.9% in FY 2019). The increase in margin was driven by lower expenses.분석 기사 • Feb 20What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?Kolinpharma S.p.A. ( BIT:KIP ), might not be a large cap stock, but it maintained its current share price over the past...Is New 90 Day High Low • Jan 11New 90-day high: €8.52The company is up 2.0% from its price of €8.36 on 13 October 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.98 per share.분석 기사 • Dec 28Is Weakness In Kolinpharma S.p.A. (BIT:KIP) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?It is hard to get excited after looking at Kolinpharma's (BIT:KIP) recent performance, when its stock has declined 7.1...Is New 90 Day High Low • Dec 18New 90-day low: €7.96The company is down 8.0% from its price of €8.64 on 18 September 2020. The Italian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.27 per share.분석 기사 • Nov 22These 4 Measures Indicate That Kolinpharma (BIT:KIP) Is Using Debt Reasonably WellLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Is New 90 Day High Low • Oct 30New 90-day low: €8.00The company is down 7.0% from its price of €8.60 on 31 July 2020. The Italian market is down 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Personal Products industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.68 per share.Price Target Changed • Oct 17Price target lowered to €11.69Down from €13.05, the current price target is an average from 2 analysts. The new target price is 40% above the current share price of €8.34. As of last close, the stock is down 18% over the past year.Is New 90 Day High Low • Oct 13New 90-day low: €8.36The company is down 5.0% from its price of €8.76 on 15 July 2020. The Italian market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.65 per share.공시 • Jul 31An undisclosed buyer acquired 12.2% stake in Kolinpharma S.p.A. (BIT:KIP) from Rita Paola Petrelli.An undisclosed buyer acquired 12.2% stake in Kolinpharma S.p.A. (BIT:KIP) from Rita Paola Petrelli on April 22, 2020. Pursuant to the terms of the transaction, Rita Paola Petrelli sold 0.2 million Kolinpharma shares. As a result of the transaction, stake of Rita Paola Petrelli has decreased from 71.82% to 59.62%. An undisclosed buyer completed the acquisition of 12.2% stake in Kolinpharma S.p.A. (BIT:KIP) from Rita Paola Petrelli on April 22, 2020.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 KIP 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: KIP 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Kolinpharma 배당 수익률 vs 시장KIP의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (KIP)n/a시장 하위 25% (IT)1.6%시장 상위 25% (IT)4.5%업계 평균 (Personal Products)2.6%분석가 예측 (KIP) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 KIP 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 KIP 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 KIP 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: KIP 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIT 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/11/01 01:53종가2023/09/27 00:00수익2022/12/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Kolinpharma S.p.A.는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Luigi TardellaEnVent Capital Markets LimitedLuisa PrimiIR Top Consulting S.r.l.
Valuation Update With 7 Day Price Move • Jun 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €9.45, the stock trades at a trailing P/E ratio of 44.4x. Average forward P/E is 23x in the Personal Products industry in Italy. Total returns to shareholders of 6.4% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.99 per share.
분석 기사 • Jun 17Kolinpharma (BIT:KIP) Is Looking To Continue Growing Its Returns On CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Reported Earnings • Mar 24Full year 2022 earnings releasedFull year 2022 results: Revenue: €15.6m (up 23% from FY 2021). Net income: €342.3k (down 46% from FY 2021). Profit margin: 2.2% (down from 5.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.8% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Personal Products industry in Italy.
Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improved over the past weekAfter last week's 19% share price gain to €8.40, the stock trades at a trailing P/E ratio of 58x. Average forward P/E is 21x in the Personal Products industry in Italy. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.25 per share.
분석 기사 • Dec 01What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?Kolinpharma S.p.A. ( BIT:KIP ), is not the largest company out there, but it saw significant share price movement...
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Chairman of the Board of Statutory Auditors Pierluigi Pipolo was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0.23 in 1H 2021)First half 2022 results: EPS: €0 (down from €0.23 in 1H 2021). Revenue: €6.90m (up 13% from 1H 2021). Net loss: €26.9k (down 107% from profit in 1H 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Personal Products industry in Italy.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Chairman of the Board of Statutory Auditors Pierluigi Pipolo was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Price Target Changed • Apr 14Price target increased to €13.45Up from €12.38, the current price target is an average from 2 analysts. New target price is 60% above last closing price of €8.42. Stock is up 2.7% over the past year.
Buying Opportunity • Apr 06Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 7.7%. The fair value is estimated to be €11.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company has become profitable.
Buying Opportunity • Feb 04Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 6.1%. The fair value is estimated to be €11.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% per annum over the last 3 years. The company has become profitable over the last 3 years.
Reported Earnings • Oct 01First half 2021 earnings releasedThe company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €6.53m (up 110% from 1H 2020). Net income: €374.9k (up €502.6k from 1H 2020). Profit margin: 5.7% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 26% share price gain to €10.30, the stock trades at a trailing P/E ratio of 26.3x. Average forward P/E is 32x in the Personal Products industry in Europe. Total returns to shareholders of 48% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €17.98 per share.
분석 기사 • Aug 25An Intrinsic Calculation For Kolinpharma S.p.A. (BIT:KIP) Suggests It's 46% UndervaluedDoes the August share price for Kolinpharma S.p.A. ( BIT:KIP ) reflect what it's really worth? Today, we will estimate...
분석 기사 • Jun 08We Think Kolinpharma (BIT:KIP) Can Stay On Top Of Its DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • May 21Do Kolinpharma's (BIT:KIP) Earnings Warrant Your Attention?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
분석 기사 • May 03Is There An Opportunity With Kolinpharma S.p.A.'s (BIT:KIP) 35% Undervaluation?Today we will run through one way of estimating the intrinsic value of Kolinpharma S.p.A. ( BIT:KIP ) by taking the...
분석 기사 • Apr 13Some Shareholders Feeling Restless Over Kolinpharma S.p.A.'s (BIT:KIP) P/E RatioWith a price-to-earnings (or "P/E") ratio of 22.3x Kolinpharma S.p.A. ( BIT:KIP ) may be sending bearish signals at the...
Reported Earnings • Apr 01Full year 2020 earnings releasedThe company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: €9.52m (down 4.8% from FY 2019). Net income: €642.4k (up 8.6% from FY 2019). Profit margin: 6.7% (up from 5.9% in FY 2019). The increase in margin was driven by lower expenses.
분석 기사 • Feb 20What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?Kolinpharma S.p.A. ( BIT:KIP ), might not be a large cap stock, but it maintained its current share price over the past...
Is New 90 Day High Low • Jan 11New 90-day high: €8.52The company is up 2.0% from its price of €8.36 on 13 October 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.98 per share.
분석 기사 • Dec 28Is Weakness In Kolinpharma S.p.A. (BIT:KIP) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?It is hard to get excited after looking at Kolinpharma's (BIT:KIP) recent performance, when its stock has declined 7.1...
Is New 90 Day High Low • Dec 18New 90-day low: €7.96The company is down 8.0% from its price of €8.64 on 18 September 2020. The Italian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.27 per share.
분석 기사 • Nov 22These 4 Measures Indicate That Kolinpharma (BIT:KIP) Is Using Debt Reasonably WellLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Is New 90 Day High Low • Oct 30New 90-day low: €8.00The company is down 7.0% from its price of €8.60 on 31 July 2020. The Italian market is down 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Personal Products industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.68 per share.
Price Target Changed • Oct 17Price target lowered to €11.69Down from €13.05, the current price target is an average from 2 analysts. The new target price is 40% above the current share price of €8.34. As of last close, the stock is down 18% over the past year.
Is New 90 Day High Low • Oct 13New 90-day low: €8.36The company is down 5.0% from its price of €8.76 on 15 July 2020. The Italian market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.65 per share.
공시 • Jul 31An undisclosed buyer acquired 12.2% stake in Kolinpharma S.p.A. (BIT:KIP) from Rita Paola Petrelli.An undisclosed buyer acquired 12.2% stake in Kolinpharma S.p.A. (BIT:KIP) from Rita Paola Petrelli on April 22, 2020. Pursuant to the terms of the transaction, Rita Paola Petrelli sold 0.2 million Kolinpharma shares. As a result of the transaction, stake of Rita Paola Petrelli has decreased from 71.82% to 59.62%. An undisclosed buyer completed the acquisition of 12.2% stake in Kolinpharma S.p.A. (BIT:KIP) from Rita Paola Petrelli on April 22, 2020.